AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02112981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus Eluting Coronary Stent
Description: BioMimeTM Sirolimus Eluting Stent (CE Marked) has cobalt chromium NexGenTM platform (CE Marked) with Tamarin BlueTM balloon Delivery System (CE marked and with FDA clearance under 510k). Stent is coated with combination of Sirolimus drug and Biodegradable PLLA and PDLG polymers.
Study NCT02112981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting Coronary stent
Description: Xience V/Xience Xpedition/Xience Prime stent is MULTI-LINK MINI VISION or MULTI-LINK VISION platform Cobalt chromium stent with Everolimus (active ingredient) embedded in a non-erodible polymer (inactive ingredient).
Study NCT01391221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
Study NCT02134587 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multifaceted educational intervention
Description: 1. Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance.~2. Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material~3. Distribution of educational material~4. Practical class to explain the correct fill of adverse drug events form~5. Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance.
Study NCT02453685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Injected s.c./subcutaneously once daily with the largest meal Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
Study NCT02453685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected s.c./subcutaneously once daily at the same time every day, with the possibility of treatment intensification with insulin aspart (Basal-bolus arm) Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
Study NCT02453685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected s.c./subcutaneously once daily.
Study NCT02622165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The REWARD serious game intervention
Description: The REWARD intervention is based on the dual process model incorporating strategies to influence both the automatic pathway (i.e., operant learning theory) and the conscious pathway (i.e., a focus on certain determinants). The central idea of the intervention will be that participants will earn credits in the game when scanning healthy (rather than unhealthy) snacks which will influence the advancement of the players in the game. This credit system will be related to the dietary quality index of the consumed snacks.
Study NCT02925611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Study NCT02925611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Study NCT01625351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Patients receive alemtuzumab on days -14 through -12 (Day 0 = stem cell transplantation).
Study NCT01625351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Patients receive fludarabine phosphate on days -11 through -7. (Day 0 = stem cell transplantation.)
Study NCT01625351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Patients receive sirolimus beginning on day -1 with taper beginning on day 90. (Day 0 = stem cell transplantation.)~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy.
Study NCT01625351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Patients receive busulfan on days -6 through -3. (Day 0 = stem cell transplantation.)
Study NCT01625351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Patients receive melphalan on days -2 and -1. (Day 0 = stem cell transplantation.)
Study NCT01625351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cells
Description: Patients undergo CD3 depleted haploidentical hematopoietic stem cell transplant (HSCT) on day 0. Patients also undergo CD45RA depleted HSCT infusion on day 1. (Day 0 = stem cell transplantation.)
Study NCT01625351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study NCT03345498 — intervention group
Intervention type: DRUG
Intervention: Entecavir
Description: Entecavir is the antiviral drug of choice recommended for hepatitis B virus treatment in presence of decompensated cirrhosis
Study NCT03371875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated transition care reminders
Description: The CHICA system will gather the elements of the TRAQ questionnaire and report the specific areas of deficiency to the physician. If a patient reaches the point of care transition (18 years), then an automated email is sent to a clinic nurse.
Study NCT01821261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouth Rinse 19668-012
Description: 20 ml of experimental mouth rinse 19668-012 for 30 seconds, twice daily
Study NCT01821261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mouth Rinse 500347078842
Description: 10 ml of mouth rinse 500347078842 for 60 seconds, twice daily
Study NCT01821261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste 035000513007
Description: Approximately one inch of toothpaste 035000513007, twice daily
Study NCT01821261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste 035000513007
Description: Approximately one inch of toothpaste 035000513007, twice daily
Study NCT06059170 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LARS score/ EORTC QLQ C30
Description: administering questionnaire
Study NCT01144910 — intervention group
Intervention type: OTHER
Intervention: methacholine challenge test
Description: 2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
Study NCT01821261 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Toothpaste 035000513007
Description: Approximately one inch of toothpaste 035000513007, twice daily
Study NCT01542606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NORMA-SENSE
Description: The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
Study NCT04881006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg tablets
Description: Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Study NCT04881006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Farxiga® 10 mg tablets
Description: Manufactured by AstraZeneca Pharmaceuticals LP
Study NCT02571517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Patients assigned to experimental group (group 1) will receive iv methylprednisolone 2 mg/kg/day (divided in two doses) doses and/or oral prednisolone 2,5 mg/kg/day (divided in two doses) during 7 days.
Study NCT02571517 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients assigned to control group (group 2) will receive iv/oral glucose 5% solution as placebo, 2 mg/kg/day (divided in two doses) during 7 days.
Study NCT04980118 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: A nutritional intervention program that consisted of two individual nutritional consults.
Study NCT04980118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and physical activity group
Description: A nutritional and physical activity intervention program that consisted of two individual nutritional consults and five nutritional group lectures.
Study NCT01132456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent treatment
Description: Endeavor RESOLUTE Zotarolimus-Eluting Coronary Stent Implantation
Study NCT03508895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole hemp seed protein
Description: The intervention was provided in the form of a smoothie.
Study NCT03508895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole hemp seed protein plus bioactive peptides
Description: The intervention was provided in the form of a smoothie.
Study NCT03508895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Casein protein
Description: The intervention was provided in the form of a smoothie.
Study NCT04263870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: oral capecitabine 1000mg per m2 bid d1-14, intravenous oxaliplatin 130mg d1 per m2, sintilimab 200mg (every 3 weeks)
Study NCT02856256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RedBull® energy drink
Description: Subjects consume 25 mL of RedBull® energy drink
Study NCT03689296 — intervention group
Intervention type: OTHER
Intervention: Questionnaires (Phase 3)
Description: * CardioVascular Risk (CVR) questionnaire representation~* SF12~* Getting Better My Way~* My recovery plan~* Psycom~* Partner In Health scale
Study NCT03689296 — intervention group
Intervention type: OTHER
Intervention: Focus groups (Phase 2)
Description: Focus group interviews conducted by two health sociologists in 4 distinct categories: caregivers, patients, primary health care professionals and psychiatric professionals.
Study NCT03689296 — intervention group
Intervention type: OTHER
Intervention: semi-structured interviews (Phase 1)
Description: Conduct of exploratory semi-directive interviews with users, caregivers, primary health care professionals and psychiatric professionals by a health sociologist
Study NCT02252393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intraoperative complication management/prevention
Description: Undergo RARC with EUD
Study NCT02252393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT03157609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermometry
Description: Within the same patient comparison of 2 thermometry methods: SpotOn skin sensor versus oesophageal temperature probe
Study NCT03157609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermometry
Description: Within the same patient comparison of 2 thermometry methods: SpotOn skin sensor versus oesophageal temperature probe
Study NCT01507805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EA preconditioning
Description: EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)with electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
Study NCT01507805 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham EA preconditioning
Description: Patients in Sham EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)without electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
Study NCT02792465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-402257
Study NCT02792465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study NCT03295487 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-O
Description: transobturator tape has been applied to all the patients in the study,and local estrogen vaginal cream is only applied to patients in group A
Study NCT04207827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: xSmoker app
Description: xSmoker - mHealth intervention consisted of using the app xSmoker
Study NCT04207827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Text messages with content based on the Motivation and Problem Solving approach and informed by our prior work.
Study NCT04207827 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual postnatal care
Study NCT00686881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (PegIFN-2b)
Description: PegIFN-2b administered at a dose of 0.5 ug/kg SC once a week for 156 weeks
Study NCT00686881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Stronger neo minophagen C (SNMC)
Description: SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .
Study NCT00789087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Videothoracoscopic talc poudrage (VT).
Description: Videothoracoscopic talc poudrage
Study NCT00789087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Talc slurry through a chest tube (DT).
Description: Talc slurry through a chest tube
Study NCT00769548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Drug used for TAS.
Study NCT03127735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1436032
Description: BAY1436032 administered continuously as a single agent dosed twice a day orally on Days 1 to 28 of a 28-day cycle.~Patients may continue treatment with BAY1436032 until disease progression, development of other unacceptable toxicity or Investigator discretion.
Study NCT03322761 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Systematic exercise training
Description: Combination of standard medical treatment and systematic early exercise training in persons with MS.
Study NCT03322761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: Informations regarding health benefits of physical activity and exercise.
Study NCT06389903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment
Description: post-surgery behavioral assessment using scales
Study NCT02547389 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community support group
Study NCT02547389 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Printed material Supported
Study NCT02788409 — intervention group
Intervention type: OTHER
Intervention: Not applicable for study
Description: Provide external perspective on background second primary cancer incidence rates for REASSURE study.
Study NCT03243669 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High-definition
Description: High-definition colonoscopy
Study NCT03243669 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Virtual chromoendoscopy
Description: Virtual chromoendoscopy
Study NCT00769548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Drug used for TAS.
Study NCT00769548 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Description: radiation therapy
Study NCT04341506 — intervention group
Intervention type: DEVICE
Intervention: Non-contact ECG
Description: A non-contact ECG will be used to detect a patient cardiac electrical activity.
Study NCT01299948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: 5 mg prednisolone orally per day
Study NCT01299948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 5 mg prednisolone orally per day
Study NCT02320565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Laparoscopy
Description: 3D Laparoscopy approach
Study NCT02320565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Laparoscopy
Description: Standard laparoscopy approach
Study NCT02925676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyposafe H02
Description: hypoglycaemia notification device
Study NCT04629482 — intervention group
Intervention type: OTHER
Intervention: Brain networks activity
Description: The brain network activity under different conditions will be evaluated by magnetoencephalography, including resting, listen to different types of music, watch different types of videos, and interacting with cognitive stimulation conditions.
Study NCT00003500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT04616261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: 6 weeks of training
Study NCT04616261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: inhalation of 54 microg formoterol
Study NCT04616261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inhalation of placebo
Study NCT00541450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sitagliptin phosphate (sitagliptin)
Description: sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period
Study NCT00541450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate (+) metformin hydrochloride
Description: sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period
Study NCT00541450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: pioglitazone
Description: pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.
Study NCT00541450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to pioglitazone
Description: matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period.~Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks.
Study NCT00541450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo to sitagliptin
Description: matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.
Study NCT00541450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo to Sita/Met FDC
Description: matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
Study NCT01869842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
Study NCT01869842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT-guided percutaneous coronary intervention
Description: the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
Study NCT02262533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study NCT02262533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Study NCT03011632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Nasal
Description: a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% Sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months
Study NCT03011632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo mometasone
Description: a group of children without IgE-dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
Study NCT00137566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen (paracetamol)
Description: Paracetamol tablets, 50 mg/kg/day for 3 days.
Study NCT00137566 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01417689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Encouragement to attempt eye drop instillation with a specific technique
Description: Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.